A Phase 2 interventional study of FF/GW642444M and GW642444M in Asthma, sponsored by GlaxoSmithKline. Completed at 4 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-01-18.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing fluticasone furoate in Asthma — none open to participants now, 3 under way, 2 of them phase 3. fluticasone furoate · Asthma.
Among the 40 studies testing fluticasone furoate in Asthma, this one is the 31st largest by enrollment, is one of 7 that started in 2010, is one of 12 in phase 2, and was the 12th registered.
4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →None of the 40 studies testing fluticasone furoate in Asthma is open now. The open studies under Asthma, anywhere →
fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 7 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 102 across the 40 interventional studies. Of the 35 that completed or were terminated, 22 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 40 have an industry lead sponsor. The 4 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 185th largest by enrollment of the 238 interventional ones that give a count, is one of 34 that started in 2010, is one of 59 in phase 2, and was the 91st registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
1 of the studies testing fluticasone furoate in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
Add it to your calendar (.ics) → With an account.
Among the 40 studies testing fluticasone furoate in Asthma, from their registry updates:
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
We propose to use an inhaled allergen challenge model to explore the individual contributions of the components of a novel long-acting beta agonist/ inhaled corticosteroid combination product and its components on protection from allergic triggers in asthma
Asthma is an increasingly common disease and is essentially caused by an allergic type of reaction of the immune system. Airways of the lungs become inflamed and narrow as a result of a reaction to triggers like chemicals (house-hold cleaning products, pollution) and allergens (house dust mite and cat or dog fur). The airways become blocked, causing shortness of breath and wheezing. The purpose of this study is to find out more information about how effective the study drugs are at protecting the lungs against allergic triggers of asthma. There are three study drugs being investigated in this study: fluticasone furoate on its own, GW642444M on its own and a combination of fluticasone furoate (FF) and GW642444M.
FF is a corticosteroid that is being developed by for the treatment of asthma. A nasal spray formulation of FF has been approved for marketing in the USA, Europe and Japan for the treatment of hayfever (rhinitis) but the dry powder formulation used in this study is not yet approved.
GW642444M is a long-acting beta2-agonist being developed by GSK for the treatment of chronic obstructive pulmonary disease (COPD). It works by acting on cells in the lungs, causing some of the muscles around the lungs to relax and open up better (bronchodilation), making breathing easier. The combination of FF/GW642444M is being developed as a once-daily treatment for both asthma and COPD.
Study treatment will be taken for 21 days in each period (4 treatment periods: FF alone, GW642444M alone, FF/GW64244M combination and placebo) and each subject will receive all treatments. On D21 subjects will undergo an allergen challenge, followed by a methacholine challenge on D22. The washout between treatment periods will be 21-35 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Current or chronic history of liver disease, or known hepatic or biliary abnormalities
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Fluticasone Furoate
Drug: FF/GW642444M
Drug: GW642444M
Drug: Placebo
Drug page: Vilanterol trifenatate
Late Asthmatic Response (LAR): Absolute Change From Saline in Minimum FEV1 Between 4-10 Hours (Hrs) Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period
Forced expiratory volume in one second (FEV1) is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen (administered by inhalation) 1 hr after dosing on Day 21. Minimum FEV1 over 4-10 hours post-allergen challenge (minimum LAR) is the minimum value of all of the post-saline time points between 4 and 10 hrs post-allergen challenge, inclusive of the 4 hr and 10 hr timepoints (i.e., minimum over 4 hrs, 4.5 hrs, 5 hrs, 5.5 hrs, 6 hrs, 6.5 hrs, 7 hrs, 7.5 hrs, 8 hrs, 8.5 hrs, 9 hrs, 9.5 hrs, and 10 hrs). Absolute change from saline in minimum FEV1 was calculated as the minimum FEV1 minus the saline FEV1 value. After inhalation of saline, 3 single measurements of FEV1 were recorded; the maximum FEV1 value was taken as the saline value. Least squares means were obtained by adjusting for period and participant and period Baselines.
Time frame: Day 21 of each treatment period (up to Study Day 197)
LAR: Absolute Change From Saline in Weighted Mean (WM) FEV1 Between 4-10 Hrs Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 1 hour after dosing on Day 21. LAR FEV1 was measured 4 hrs, 4.5 hrs, 5 hrs, 5.5 hrs, 6 hrs, 6.5 hrs, 7 hrs, 7.5 hrs, 8 hrs, 8.5 hrs, 9 hrs, 9.5 hrs, and 10 hrs post-allergen challenge on Day 21. Absolute change from saline in WM FEV1 was calculated as the area under the curve divided by the relevant time interval and subtracting the saline FEV1 value. After inhalation of saline, 3 single measurements of FEV1 were recorded; the maximum FEV1 value was taken as the saline value. Least squares means were obtained by adjusting for period and participant and period Baselines.
Time frame: Day 21 of each treatment period (up to Study Day 197)
Early Asthmatic Response (EAR): Absolute Change From Saline in Minimum FEV1 Between 0-2 Hrs Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 1 hr after dosing on Day 21. Minimum FEV1 over 0-2 hrs post-allergen challenge (Minimum EAR) is the minimum value of all of the post-allergen challenge timepoints up to and including 2 hours post-allergen challenge (i.e., minimum over 5 minutes (min), 10 min, 15 min, 20 min, 30 min, 45 min and 1 hr, 1.5 hrs, and 2 hrs. Absolute change from saline in minimum FEV1 was calculated as the minimum FEV1 minus the saline FEV1 value. After inhalation of saline, 3 single measurements of FEV1 were recorded; the maximum FEV1 value was taken as the saline value. Least squares means were obtained by adjusting for period and participant and period Baselines.
Time frame: Day 21 of each treatment period (up to Study Day 197)
EAR: Absolute Change From Saline in Weighted Mean FEV1 Between 0-2 Hrs Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 1 hr after dosing on Day 21. The EAR FEV1 was measured 0 minutes (min), 5 min, 10 min, 15 min, 20 min, 30 min, 45 min, 1 hr, 1.5 hrs, and 2 hrs post-allergen challenge on Day 21. Least squares means were obtained by adjusting for period and participant and period Baselines. Absolute change from saline in WM FEV1 was calculated as the area under the curve divided by the relevant time interval and subtracting the saline FEV1 value. After inhalation of saline, 3 single measurements of FEV1 were recorded; the maximum FEV1 value was taken as the saline value.
Time frame: Day 21 of each treatment period (up to Study Day 197)
Maximum Percent Change From Saline in FEV1 Between 0-2 Hrs, Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 1 hr after dosing on Day 21. FEV1 was measured 0 minutes (min), 5 min, 10 min, 15 min, 20 min, 30 min, 45 min, 1 hr, 1.5 hrs, and 2 hrs post-allergen challenge on Day 21. Maximum percent change was calculated as the minimum FEV1 minus the saline FEV1 value divided by the saline FEV1 multiplied by 100. After inhalation of saline, 3 single measurements of FEV1 were recorded; the maximum FEV1 value was taken as the saline FEV1 value.
Time frame: Day 21 of each treatment period (up to Study Day 197)
Provocative Concentration of Methacholine Estimated to Result in a 20% Reduction in FEV1 (PC20) on Day 22 of Each Treatment Period
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants inhaled doubling increments of methacholine until a \>=20% fall in FEV1 from the saline value was achieved. After inhalation of saline, 3 measurements of FEV1 were recorded; the maximum FEV1 value was taken as the saline value.
Time frame: Day 22 of each treatment period (up to Study Day 198)
| Milestone | Sequence 1: VI 25 µg, Placebo, FF 100 µg, FF/VI 100/25 µg | Sequence 2: FF/VI 100/25 µg, FF 100 µg, Placebo, VI 25 µg | Sequence 3: Placebo, FF/VI 100/25 µg, VI 25 µg, FF 100 µg | Sequence 4: FF 100 µg, VI 25 µg, FF/VI 100/25 µg, Placebo |
|---|---|---|---|---|
| Started | 7 | 6 | 7 | 7 |
| Completed | 7 | 6 | 7 | 7 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1: VI 25 µg, Placebo, FF 100 µg, FF/VI 100/25 µg | Sequence 2: FF/VI 100/25 µg, FF 100 µg, Placebo, VI 25 µg | Sequence 3: Placebo, FF/VI 100/25 µg, VI 25 µg, FF 100 µg | Sequence 4: FF 100 µg, VI 25 µg, FF/VI 100/25 µg, Placebo |
|---|---|---|---|---|
| Started | 7 | 6 | 7 | 7 |
| Completed | 7 | 6 | 7 | 7 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1: VI 25 µg, Placebo, FF 100 µg, FF/VI 100/25 µg | Sequence 2: FF/VI 100/25 µg, FF 100 µg, Placebo, VI 25 µg | Sequence 3: Placebo, FF/VI 100/25 µg, VI 25 µg, FF 100 µg | Sequence 4: FF 100 µg, VI 25 µg, FF/VI 100/25 µg, Placebo |
|---|---|---|---|---|
| Started | 7 | 6 | 7 | 7 |
| Completed | 7 | 6 | 7 | 7 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1: VI 25 µg, Placebo, FF 100 µg, FF/VI 100/25 µg | Sequence 2: FF/VI 100/25 µg, FF 100 µg, Placebo, VI 25 µg | Sequence 3: Placebo, FF/VI 100/25 µg, VI 25 µg, FF 100 µg | Sequence 4: FF 100 µg, VI 25 µg, FF/VI 100/25 µg, Placebo |
|---|---|---|---|---|
| Started | 7 | 6 | 7 | 7 |
| Completed | 7 | 6 | 7 | 7 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1: VI 25 µg, Placebo, FF 100 µg, FF/VI 100/25 µg | Sequence 2: FF/VI 100/25 µg, FF 100 µg, Placebo, VI 25 µg | Sequence 3: Placebo, FF/VI 100/25 µg, VI 25 µg, FF 100 µg | Sequence 4: FF 100 µg, VI 25 µg, FF/VI 100/25 µg, Placebo |
|---|---|---|---|---|
| Started | 7 | 6 | 7 | 7 |
| Completed | 7 | 5 | 7 | 7 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
| Milestone | Sequence 1: VI 25 µg, Placebo, FF 100 µg, FF/VI 100/25 µg | Sequence 2: FF/VI 100/25 µg, FF 100 µg, Placebo, VI 25 µg | Sequence 3: Placebo, FF/VI 100/25 µg, VI 25 µg, FF 100 µg | Sequence 4: FF 100 µg, VI 25 µg, FF/VI 100/25 µg, Placebo |
|---|---|---|---|---|
| Started | 7 | 5 | 7 | 7 |
| Completed | 7 | 5 | 7 | 7 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1: VI 25 µg, Placebo, FF 100 µg, FF/VI 100/25 µg | Sequence 2: FF/VI 100/25 µg, FF 100 µg, Placebo, VI 25 µg | Sequence 3: Placebo, FF/VI 100/25 µg, VI 25 µg, FF 100 µg | Sequence 4: FF 100 µg, VI 25 µg, FF/VI 100/25 µg, Placebo |
|---|---|---|---|---|
| Started | 7 | 5 | 7 | 7 |
| Completed | 7 | 5 | 7 | 7 |
| Not completed | 0 | 0 | 0 | 0 |
Forced expiratory volume in one second (FEV1) is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen (administered by inhalation) 1 hr after dosing on Day 21. Minimum FEV1 over 4-10 hours post-allergen challenge (minimum LAR) is the minimum value of all of the post-saline time points between 4 and 10 hrs post-allergen challenge, inclusive of the 4 hr and 10 hr timepoints (i.e., minimum over 4 hrs, 4.5 hrs, 5 hrs, 5.5 hrs, 6 hrs, 6.5 hrs, 7 hrs, 7.5 hrs, 8 hrs, 8.5 hrs, 9 hrs, 9.5 hrs, and 10 hrs). Absolute change from saline in minimum FEV1 was calculated as the minimum FEV1 minus the saline FEV1 value. After inhalation of saline, 3 single measurements of FEV1 were recorded; the maximum FEV1 value was taken as the saline value. Least squares means were obtained by adjusting for period and participant and period Baselines.
| Liters | Placebo | FF/VI 100/25 µg OD | FF 100 µg OD | VI 25 µg OD |
|---|---|---|---|---|
| Late Asthmatic Response (LAR): Absolute Change From Saline in Minimum FEV1 Between 4-10 Hours (Hrs) Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period | -0.731 (-0.878 to -0.584) | -0.216 (-0.343 to -0.088) | -0.188 (-0.315 to -0.061) | -0.536 (-0.676 to -0.396) |
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 1 hr after dosing on Day 21. FEV1 was measured 0 minutes (min), 5 min, 10 min, 15 min, 20 min, 30 min, 45 min, 1 hr, 1.5 hrs, and 2 hrs post-allergen challenge on Day 21. Maximum percent change was calculated as the minimum FEV1 minus the saline FEV1 value divided by the saline FEV1 multiplied by 100. After inhalation of saline, 3 single measurements of FEV1 were recorded; the maximum FEV1 value was taken as the saline FEV1 value.
| percent change | Placebo | FF/VI 100/25 µg OD | FF 100 µg OD | VI 25 µg OD |
|---|---|---|---|---|
| Maximum Percent Change From Saline in FEV1 Between 0-2 Hrs, Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period | -26.13 (-58.9 to -5.4) | -10.43 (-58.9 to -2.1) | -16.14 (-64.9 to -4.0) | -18.35 (-59.3 to -4.4) |
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants inhaled doubling increments of methacholine until a \>=20% fall in FEV1 from the saline value was achieved. After inhalation of saline, 3 measurements of FEV1 were recorded; the maximum FEV1 value was taken as the saline value.
| milligrams per milliliter | Placebo | FF/VI 100/25 µg OD | FF 100 µg OD | VI 25 µg OD |
|---|---|---|---|---|
| Provocative Concentration of Methacholine Estimated to Result in a 20% Reduction in FEV1 (PC20) on Day 22 of Each Treatment Period | 1.046 ± 3.3191 | 2.500 ± 3.7363 | 2.492 ± 5.3371 | 0.387 ± 0.5311 |
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 1 hour after dosing on Day 21. LAR FEV1 was measured 4 hrs, 4.5 hrs, 5 hrs, 5.5 hrs, 6 hrs, 6.5 hrs, 7 hrs, 7.5 hrs, 8 hrs, 8.5 hrs, 9 hrs, 9.5 hrs, and 10 hrs post-allergen challenge on Day 21. Absolute change from saline in WM FEV1 was calculated as the area under the curve divided by the relevant time interval and subtracting the saline FEV1 value. After inhalation of saline, 3 single measurements of FEV1 were recorded; the maximum FEV1 value was taken as the saline value. Least squares means were obtained by adjusting for period and participant and period Baselines.
| Liters | Placebo | FF/VI 100/25 µg OD | FF 100 µg OD | VI 25 µg OD |
|---|---|---|---|---|
| LAR: Absolute Change From Saline in Weighted Mean (WM) FEV1 Between 4-10 Hrs Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period | -0.466 (-0.589 to -0.343) | 0.018 (-0.089 to 0.125) | 0.018 (-0.089 to 0.124) | -0.298 (-0.415 to -0.181) |
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 1 hr after dosing on Day 21. Minimum FEV1 over 0-2 hrs post-allergen challenge (Minimum EAR) is the minimum value of all of the post-allergen challenge timepoints up to and including 2 hours post-allergen challenge (i.e., minimum over 5 minutes (min), 10 min, 15 min, 20 min, 30 min, 45 min and 1 hr, 1.5 hrs, and 2 hrs. Absolute change from saline in minimum FEV1 was calculated as the minimum FEV1 minus the saline FEV1 value. After inhalation of saline, 3 single measurements of FEV1 were recorded; the maximum FEV1 value was taken as the saline value. Least squares means were obtained by adjusting for period and participant and period Baselines.
| Liters | Placebo | FF/VI 100/25 µg OD | FF 100 µg OD | VI 25 µg OD |
|---|---|---|---|---|
| Early Asthmatic Response (EAR): Absolute Change From Saline in Minimum FEV1 Between 0-2 Hrs Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period | -1.091 (-1.344 to -0.837) | -0.614 (-0.858 to -0.370) | -0.826 (-1.070 to -0.581) | -0.955 (-1.209 to -0.702) |
FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. Participants were exposed to an allergen 1 hr after dosing on Day 21. The EAR FEV1 was measured 0 minutes (min), 5 min, 10 min, 15 min, 20 min, 30 min, 45 min, 1 hr, 1.5 hrs, and 2 hrs post-allergen challenge on Day 21. Least squares means were obtained by adjusting for period and participant and period Baselines. Absolute change from saline in WM FEV1 was calculated as the area under the curve divided by the relevant time interval and subtracting the saline FEV1 value. After inhalation of saline, 3 single measurements of FEV1 were recorded; the maximum FEV1 value was taken as the saline value.
| Liters | Placebo | FF/VI 100/25 µg OD | FF 100 µg OD | VI 25 µg OD |
|---|---|---|---|---|
| EAR: Absolute Change From Saline in Weighted Mean FEV1 Between 0-2 Hrs Following the 1-hr Post-treatment Allergen Challenge on Day 21 of Each Treatment Period | -0.560 (-0.745 to -0.374) | -0.297 (-0.476 to -0.118) | -0.386 (-0.565 to -0.207) | -0.533 (-0.718 to -0.348) |
Collected over Serious adverse events (SAEs) and non-serious AEs were collected from the start of study medication to the end of the fourth treatment period (up to Day 210).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/27 (0%) | 19/27 (70.4%) |
| FF/VI 100/25 µg OD | — | 0/27 (0%) | 20/27 (74.1%) |
| FF 100 µg OD | — | 0/27 (0%) | 19/27 (70.4%) |
| VI 25 µg OD | — | 0/26 (0%) | 22/26 (84.6%) |
| Event | Placebo | FF/VI 100/25 µg OD | FF 100 µg OD | VI 25 µg OD |
|---|---|---|---|---|
| HeadacheNervous system disorders | 11/27 | 15/27 | 15/27 | 13/26 |
| NasopharyngitisInfections and infestations | 2/27 | 3/27 | 2/27 | 5/26 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 2/27 | 3/27 | 2/27 | 3/26 |
| Seasonal allergyImmune system disorders | 0/27 | 1/27 | 3/27 | 1/26 |
| DiarrhoeaGastrointestinal disorders | 1/27 | 0/27 | 0/27 | 2/26 |
| Viral upper respiratory tract infectionInfections and infestations | 1/27 | 2/27 | 0/27 | 0/26 |
| Oral candidiasisInfections and infestations | 2/27 | 0/27 | 0/27 | 0/26 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/27 | 2/27 | 1/27 | 0/26 |
| DysmenorrhoeaReproductive system and breast disorders | 2/27 | 0/27 | 1/27 | 0/26 |
| Upper respiratory tract infectionInfections and infestations | 1/27 | 0/27 | 0/27 | 1/26 |
| Age, Continuous(Years) | Placebo, FF/VI 100/25 µg OD, FF 100 µg OD, VI 25 µg |
|---|---|
| Mean | 30.8 ± 7.46 |
| Gender(Participants) | Placebo, FF/VI 100/25 µg OD, FF 100 µg OD, VI 25 µg |
|---|---|
| Female | 8 |
| Male | 19 |
| Race/Ethnicity, Customized(participants) | Placebo, FF/VI 100/25 µg OD, FF 100 µg OD, VI 25 µg |
|---|---|
| White/Caucasian/European Heritage | 25 |
| East Asian Heritage | 1 |
| Mixed Race | 1 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of May 2010, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2013, 2 years 3 months after primary completion. A results delay was requested in Feb 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Vilanterol trifenatate · Fluticasone furoate